Hepion Pharmaceuticals
phase studies completed safe and well tolerated key findings | Hepion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
14 of 34
Related slides by other companies
Equillium
Investor Presentation
February 2024
phase study of in adults with moderate to severe potential target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
MindMed
Investor Presentation
January 2025
regulatory elements supporting filing requirements | MindMed
RenovoRx
IPO
August 2021
designed for success one phase trial to approval pivotal tiger pac phase study schema currently enrolling | RenovoRx
Xeris Biopharma
Investor Presentation
October 2022
topline results of phase study of | Xeris Biopharma
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights